var data={"title":"Clostridium difficile infection in children: Treatment and outcome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clostridium difficile infection in children: Treatment and outcome</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/contributors\" class=\"contributor contributor_credentials\">Jonathan Crews, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 20, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Clostridium difficile</em> is an important cause of antibiotic-associated diarrhea and one of the most common healthcare-associated pathogens [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/1\" class=\"abstract_t\">1</a>]. Its clinical manifestations range from asymptomatic colonization or mild diarrhea to fulminant disease characterized by ileus, toxic megacolon, hypotension, or shock. <em>C. difficile</em> infection is less common in children than adults, but the incidence of <em>C. difficile</em> infection in children is increasing [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/2-5\" class=\"abstract_t\">2-5</a>].</p><p>The treatment of and outcomes associated with <em>C. difficile</em> infection in children will be discussed here. The pathogenesis, epidemiology, clinical features, diagnosis, and prevention of <em>C. difficile</em> are discussed separately. (See <a href=\"topic.htm?path=clostridium-difficile-infection-in-children-microbiology-pathogenesis-and-epidemiology\" class=\"medical medical_review\">&quot;Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology&quot;</a> and <a href=\"topic.htm?path=clostridium-difficile-infection-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Clostridium difficile infection in children: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=clostridium-difficile-infection-prevention-and-control\" class=\"medical medical_review\">&quot;Clostridium difficile infection: Prevention and control&quot;</a>.)</p><p><em>C. difficile</em> infection in adults also is discussed separately. (See <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-epidemiology-microbiology-and-pathophysiology\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Epidemiology, microbiology, and pathophysiology&quot;</a> and <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-treatment-and-prevention\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Treatment and prevention&quot;</a>.)</p><p>There is limited high-quality evidence to guide the management of <em>C. difficile</em> infection in children. Most treatment recommendations are extrapolated from studies performed in adults. The treatment guidelines presented below are largely compatible with the recommendations of the American Academy of Pediatrics Committee on Infectious Diseases (2015), the <a href=\"http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infections_By_Organ_System-81567/Gastrointestinal/Clostridium_difficile/&amp;token=i8NlHdBi1m60LfSzulei7UCtxdHmsNh0m7manrjRvFUG9arU/GP9rXn/qHpO6WyUiINLzyt26elD2kR2syCtq57ihqvAsyzYuIgSftbPBgSdq4mWuOLVbblV0QJbX+xeg8sBfKimLkhdPeuWLpUaU9b/Q5PBVVhHZQDEiL3g234=&amp;TOPIC_ID=6050\" target=\"_blank\" class=\"external\">Infectious Diseases Society of America and Society for Healthcare Epidemiology of America</a> (2017), and <a href=\"http://gi.org/clinical-guidelines/clinical-guidelines-sortable-list/&amp;token=aVq4uQ0uZ9jSKdZI4ulLsRoW8/kDUNnaZeScHfWTMlWiSrIwK2bX/6RtMCc66pdEd78QYK7qXEV6Y/Ni59xsoA==&amp;TOPIC_ID=6050\" target=\"_blank\" class=\"external\">the American College of Gastroenterology</a> (2013) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6-8\" class=\"abstract_t\">6-8</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">GENERAL MEASURES</span></p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Discontinuation of inciting antibiotics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Discontinuation of the inciting antibiotic is important in the management of <em>C. difficile </em>infection [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6-8\" class=\"abstract_t\">6-8</a>]. The use of concomitant antibiotics (ie, antibiotics other than those used to treat <em>C. difficile</em>) during treatment for <em>C. difficile</em> infection has been shown to prolong the duration of symptoms and increase the risk of recurrence in adults [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/9\" class=\"abstract_t\">9</a>]. In children, the use of concomitant antibiotics has been associated with recurrent disease [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/10\" class=\"abstract_t\">10</a>]. If an ongoing infection requires continued antibiotic treatment, we suggest modifying therapy to achieve the narrowest spectrum and shortest duration possible. (See <a href=\"topic.htm?path=clostridium-difficile-infection-in-children-microbiology-pathogenesis-and-epidemiology#H14\" class=\"medical medical_review\">&quot;Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology&quot;, section on 'Antibiotic exposure'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Supportive care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Supportive care for children with diarrhea from <em>C. difficile</em> includes correction of fluid losses and electrolyte imbalances [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"topic.htm?path=clinical-assessment-and-diagnosis-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">&quot;Clinical assessment and diagnosis of hypovolemia (dehydration) in children&quot;</a> and <a href=\"topic.htm?path=treatment-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">&quot;Treatment of hypovolemia (dehydration) in children&quot;</a>.)</p><p>Antimotility drugs (eg, <a href=\"topic.htm?path=loperamide-pediatric-drug-information\" class=\"drug drug_pediatric\">loperamide</a>) and opioids are discouraged due to concerns they may cause retention of toxins and predispose to complications such as ileus or toxic megacolon although this association has not been observed in clinical studies [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H2248420511\"><span class=\"h2\">Indications for hospitalization</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hospitalization may be warranted for children with dehydration, electrolyte abnormalities, moderate to marked toxicity, or severe or fulminant disease (<a href=\"image.htm?imageKey=PEDS%2F100705\" class=\"graphic graphic_table graphicRef100705 \">table 1</a>). Recommendations for the prevention of <em>C. difficile</em> infection in hospital settings are discussed separately. (See <a href=\"topic.htm?path=clostridium-difficile-infection-prevention-and-control#H5497287\" class=\"medical medical_review\">&quot;Clostridium difficile infection: Prevention and control&quot;, section on 'Prevention strategies'</a>.)</p><p class=\"headingAnchor\" id=\"H3116939453\"><span class=\"h2\">Indications for antimicrobial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We initiate antimicrobial therapy in children with symptomatic <em>C. difficile</em> infection (<a href=\"image.htm?imageKey=PEDS%2F100705\" class=\"graphic graphic_table graphicRef100705 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6,7\" class=\"abstract_t\">6,7</a>]. The antimicrobial regimen depends upon the severity of disease. (See <a href=\"#H100909150\" class=\"local\">'Mild or moderate disease'</a> below and <a href=\"#H100909159\" class=\"local\">'Severe disease'</a> below.)</p><p>Empiric antimicrobial therapy, pending results of <em>C. difficile</em> testing, is not routinely recommended, but may be warranted if there is a delay in laboratory confirmation or for severe or fulminant disease (<a href=\"image.htm?imageKey=PEDS%2F71790\" class=\"graphic graphic_table graphicRef71790 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/7,13\" class=\"abstract_t\">7,13</a>].</p><p>Antimicrobial therapy is <strong>not</strong> indicated in children with asymptomatic colonization with <em>C. difficile</em> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6,7\" class=\"abstract_t\">6,7</a>]. In a randomized trial of asymptomatic adults colonized with <em>C. difficile</em>, treatment with <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> had no effect on colonization status. Treatment with <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>, while temporarily effective in eradicating detectable colonization, was associated with increased rates of carriage two months after therapy [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H100909150\"><span class=\"h1\">MILD OR MODERATE DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The majority of children with <em>C. difficile</em> infection have mild to moderate disease (<a href=\"image.htm?imageKey=PEDS%2F100705\" class=\"graphic graphic_table graphicRef100705 \">table 1</a>). Inciting antibiotics should be discontinued if possible and supportive measures provided as indicated. (See <a href=\"#H6\" class=\"local\">'General measures'</a> above.)</p><p>Either <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> or <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> is the suggested antimicrobial therapy for the treatment of an initial episode of nonsevere <em>C. difficile </em>infection in children and adolescents (<a href=\"image.htm?imageKey=PEDS%2F100705\" class=\"graphic graphic_table graphicRef100705 \">table 1</a> and <a href=\"image.htm?imageKey=PEDS%2F117235\" class=\"graphic graphic_table graphicRef117235 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6,7\" class=\"abstract_t\">6,7</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> 40 <span class=\"nowrap\">mg/kg</span> per day orally in four divided doses (maximum 125 <span class=\"nowrap\">mg/dose)</span> for 10 days, <strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Metronidazole</a> 30 <span class=\"nowrap\">mg/kg</span> per day orally in four divided doses (maximum 500 <span class=\"nowrap\">mg/dose)</span> for 10 days</p><p/><p>Studies comparing <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> and <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> for the treatment of <em>C. difficile</em> infection in children are limited. Nonetheless, observational studies and accumulated experience suggest that children with <em>C. difficile</em> infection have good outcomes with either oral metronidazole or vancomycin [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6,7,15,16\" class=\"abstract_t\">6,7,15,16</a>]. In contrast, randomized trials including adult patients have found vancomycin to be superior to metronidazole [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/7,17,18\" class=\"abstract_t\">7,17,18</a>]. In a 2017 meta-analysis of four randomized trials including 872 adult patients with nonsevere <em>C. difficile</em> infection [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/17-20\" class=\"abstract_t\">17-20</a>], vancomycin was slightly more effective than metronidazole at achieving symptomatic cure without recurrence (79 versus 72 percent, risk ratio [RR] 0.90, 95% CI 0.84-0.97) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> &ndash; Vancomycin is the only agent approved by the US Food and Drug Administration for the treatment of <em>C. difficile</em> infection in children. It is limited by its greater cost and concerns for promoting the intestinal carriage of vancomycin-resistant enterococci (VRE). However, the risk of subsequent intestinal colonization with VRE has been described with both vancomycin and <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> achieves very high fecal concentrations when administered orally because it is not absorbed. It maintains high concentrations throughout the duration of treatment [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/14\" class=\"abstract_t\">14</a>]. The oral formulation of vancomycin is more expensive than <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a>; thus, some hospitals use the generic intravenous formulation for oral administration [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/7\" class=\"abstract_t\">7</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Metronidazole</a> &ndash; Metronidazole<strong> </strong>is less expensive than <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/7\" class=\"abstract_t\">7</a>]. In addition, the use of vancomycin may promote intestinal carriage of VRE, although VRE can also occur with metronidazole [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p><a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Metronidazole</a> is rapidly absorbed when administered orally; effective fecal concentrations are achieved through biliary excretion and secretion across inflamed intestinal mucosa. Fecal concentrations peak early in illness and decline as symptoms improve [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/23\" class=\"abstract_t\">23</a>]. Metronidazole is undetectable in the stool of asymptomatic carriers [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/14\" class=\"abstract_t\">14</a>]. <em>C. difficile</em> strains with decreased susceptibility to metronidazole are rare [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/24-26\" class=\"abstract_t\">24-26</a>]. The use of metronidazole is limited by its metallic taste and side effects, primarily nausea and peripheral neuropathy (associated with prolonged administration or cumulative exposure).</p><p class=\"headingAnchor\" id=\"H100909159\"><span class=\"h1\">SEVERE DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although there is no consensus definition, we use the following clinical features to indicate severe <em>C. difficile</em> infection in children (<a href=\"image.htm?imageKey=PEDS%2F100705\" class=\"graphic graphic_table graphicRef100705 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Profuse diarrhea with systemic findings (fever, rigors, or severe abdominal pain, tenderness, or distention)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypotension or shock</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ileus or toxic megacolon</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elevated white blood cell count (&gt;15,000 <span class=\"nowrap\">cells/microL)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elevated age-adjusted serum creatinine level</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum albumin level &lt;2.5 <span class=\"nowrap\">g/dL</span> (25 <span class=\"nowrap\">g/L)</span></p><p/><p>Consultation with specialists in infectious diseases, gastrointestinal disease, <span class=\"nowrap\">and/or</span> surgery may be warranted for children with severe disease.</p><p>Data on the frequency of severe disease in children are limited by the absence of a validated definition. However, in observational studies, disease severity is overestimated when adult criteria for severe disease are applied to children [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/27,28\" class=\"abstract_t\">27,28</a>]. In observational studies, complications occur in 2 to 7 percent of children with <em>C. difficile</em> infection [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/15,27-30\" class=\"abstract_t\">15,27-30</a>].</p><p class=\"headingAnchor\" id=\"H2248421210\"><span class=\"h2\">Antimicrobial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> is the preferred agent for children and adolescents with severe or fulminant <em>C. difficile</em> infection (<a href=\"image.htm?imageKey=PEDS%2F100705\" class=\"graphic graphic_table graphicRef100705 \">table 1</a> and <a href=\"image.htm?imageKey=PEDS%2F117235\" class=\"graphic graphic_table graphicRef117235 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6,7,17\" class=\"abstract_t\">6,7,17</a>]. The dose of vancomycin is 40 <span class=\"nowrap\">mg/kg</span> per day by mouth in four divided doses (maximum 125 <span class=\"nowrap\">mg/dose)</span> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6,7\" class=\"abstract_t\">6,7</a>]. The standard duration of treatment for <em>C. difficile</em> infection is 10 days, though the course should be tailored to clinical response for children with severe or fulminant disease.</p><p>For children with fulminant disease (ie, hypotension or shock, ileus, or toxic megacolon), we suggest treatment with a higher maximum dose of <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>: 40 <span class=\"nowrap\">mg/kg</span> per day by mouth in four divided doses (maximum 500 <span class=\"nowrap\">mg/dose)</span> and decreasing to the standard maximum dose (125 <span class=\"nowrap\">mg/dose)</span> after clinical improvement (<a href=\"image.htm?imageKey=PEDS%2F117235\" class=\"graphic graphic_table graphicRef117235 \">table 3</a>). We obtain serum vancomycin levels in children with complicated disease who are receiving high-dose vancomycin (maximum 500 <span class=\"nowrap\">mg/dose)</span> because systemic absorption can occur in patients with severe colitis [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/31\" class=\"abstract_t\">31</a>]. Using an increased maximum dose of vancomycin for children with fulminant disease is suggested in the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) clinical practice guidelines for <em>C. difficile</em> infection in adults and children [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/7\" class=\"abstract_t\">7</a>]. However, there are limited data to support the efficacy of this approach.</p><p><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> is preferred over <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> for severe disease because of the increased risk of treatment failure with metronidazole in studies of adult patients [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/32-35\" class=\"abstract_t\">32-35</a>]. For example, in a randomized trial of adults with severe <em>C. difficile</em> infection (defined by pseudomembranous colitis, requiring intensive care, or two of the following: age &gt;60 years, fever &gt;38.3&deg;C [101&deg;F], albumin level &lt;2.5 <span class=\"nowrap\">g/dL,</span> or white blood cell [WBC] count &gt;15,000 <span class=\"nowrap\">cells/microL),</span> the cure rate was higher with vancomycin than metronidazole (97 versus 76 percent) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H315875231\"><span class=\"h3\">Inability to tolerate oral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with severe or fulminant disease in whom oral therapy cannot be administered (eg, ileus or toxic megacolon), intravenous <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> 30 <span class=\"nowrap\">mg/kg</span> per day in four divided doses (maximum 500 <span class=\"nowrap\">mg/dose)</span> in combination with rectal instillation of <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> is suggested (<a href=\"image.htm?imageKey=PEDS%2F117235\" class=\"graphic graphic_table graphicRef117235 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/7,36\" class=\"abstract_t\">7,36</a>]. When given as a single agent, intravenous metronidazole is less effective than either oral metronidazole or oral vancomycin [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/37\" class=\"abstract_t\">37</a>].</p><p>The optimal dose and volume for rectal <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> has not been established for children or adults; the dose used in published case series varies widely [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/38\" class=\"abstract_t\">38</a>]. For rectal instillation in adults, the <span class=\"nowrap\">IDSA/SHEA</span> guidelines recommend vancomycin 500 mg in 100 mL normal saline to be administered by retention enema four times daily [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/7\" class=\"abstract_t\">7</a>]. For children, the <span class=\"nowrap\">IDSA/SHEA</span> guidelines recommend vancomycin 10 <span class=\"nowrap\">mg/kg</span> per dose four times daily. We suggest the following age-dependent volumes for rectal instillation in children: 1 through 4 years old &ndash; 50 mL; 5 through 11 years old &ndash; 75 mL; &ge;12 years &ndash; 100 mL. Dose and volume adjustments may be required depending upon individual circumstances, extent of colonic disease, and patient weight. Caution is required because perforation is possible with rectal installation of vancomycin.</p><p class=\"headingAnchor\" id=\"H2248421190\"><span class=\"h2\">Additional measures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgery (ie, subtotal colectomy, diversion ileostomy) may be required as a life-saving measure for severely ill children with toxic megacolon, colonic perforation, acute abdomen, or septic shock. The indications for surgery in children with fulminant disease from <em>C. difficile</em> infection are not well-established. Subtotal or total colectomy is most often performed, although colon-sparing surgical techniques have been described [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/39,40\" class=\"abstract_t\">39,40</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">RESPONSE TO TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The response to treatment of <em>C. difficile</em> infection is assessed clinically. In patients with mild to moderate disease, symptoms generally improve within 48 to 72 hours after initiation of antibiotic therapy, but diarrhea may not fully resolve for four to five days [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/11,41\" class=\"abstract_t\">11,41</a>]. Responses may be slower with <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> or with infection from the <span class=\"nowrap\">NAP1/BI/027</span> strain [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/42\" class=\"abstract_t\">42</a>].</p><p>Follow-up testing for <em>C. difficile</em> is <strong>not</strong> recommended because patients can remain colonized with toxin-producing strains after recovery [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6\" class=\"abstract_t\">6</a>].</p><p>Patients remain vulnerable to recurrence of <em>C. difficile</em> infection for up to eight weeks (or longer) following treatment [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/43\" class=\"abstract_t\">43</a>]. A recurrence of gastrointestinal symptoms requires evaluation. (See <a href=\"#H36637750\" class=\"local\">'Management of recurrence'</a> below.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">MANAGEMENT OF TREATMENT FAILURE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment failure is defined as progression of disease or failure to improve after several days of therapy [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/11\" class=\"abstract_t\">11</a>]. A minority of children with <em>C. difficile</em> infection fail to respond to treatment [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/16,29,30\" class=\"abstract_t\">16,29,30</a>].</p><p>Among children with <em>C. difficile</em> infection and ongoing symptoms despite treatment, a proportion will have underlying gastrointestinal disorders [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/16\" class=\"abstract_t\">16</a>]. Ongoing symptoms can also be caused by coinfection with an additional enteric pathogen. Children with progression of disease or failure to improve after three to four days of antibiotic therapy should be evaluated (or reevaluated) for other causes of diarrhea. The possibility of an underlying predisposing condition must also be considered. (See <a href=\"topic.htm?path=clostridium-difficile-infection-in-children-clinical-features-and-diagnosis#H2444666133\" class=\"medical medical_review\">&quot;Clostridium difficile infection in children: Clinical features and diagnosis&quot;, section on 'Differential diagnosis'</a> and <a href=\"topic.htm?path=clostridium-difficile-infection-in-children-microbiology-pathogenesis-and-epidemiology#H16\" class=\"medical medical_review\">&quot;Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology&quot;, section on 'Predisposing conditions'</a>.)</p><p>The optimal management of refractory <em>C. difficile</em> infection in children is not established. If another etiology cannot be identified, we suggest discontinuing the inciting antibiotic (if this has not already occurred) and switching to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> in patients that fail to respond to treatment.</p><p class=\"headingAnchor\" id=\"H36637750\"><span class=\"h1\">MANAGEMENT OF RECURRENCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recurrent <em>C. difficile</em> infection is a return of infection after a period of symptom resolution that generally occurs within eight weeks of the initial episode [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/44\" class=\"abstract_t\">44</a>]. Recurrent episodes may represent a relapse of the previous infecting strain or reinfection with a new strain [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/45\" class=\"abstract_t\">45</a>]. (See <a href=\"topic.htm?path=clostridium-difficile-infection-in-children-clinical-features-and-diagnosis#H9\" class=\"medical medical_review\">&quot;Clostridium difficile infection in children: Clinical features and diagnosis&quot;, section on 'Recurrent infection'</a>.) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/1,10,15,30,46,47\" class=\"abstract_t\">1,10,15,30,46,47</a>]</p><p class=\"headingAnchor\" id=\"H3116940015\"><span class=\"h2\">First recurrence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The signs and symptoms of recurrence are similar to those in the initial episode. Investigation for other causes of diarrhea may be warranted because a return of diarrhea is not always due to a recurrence of <em>C. difficile</em> infection<em>.</em> Since persistence of <em>C. difficile</em> is common after effective treatment, a positive <em>C. difficile</em> test may represent asymptomatic colonization. For children with a first recurrence, a second course of treatment with the same antibiotic (either <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> or <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a>) is suggested (<a href=\"image.htm?imageKey=PEDS%2F117235\" class=\"graphic graphic_table graphicRef117235 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6,7\" class=\"abstract_t\">6,7</a>]. (See <a href=\"topic.htm?path=clostridium-difficile-infection-in-children-clinical-features-and-diagnosis#H2444666133\" class=\"medical medical_review\">&quot;Clostridium difficile infection in children: Clinical features and diagnosis&quot;, section on 'Differential diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H3116940022\"><span class=\"h2\">Subsequent recurrences</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal management of multiple recurrence of <em>C. difficile</em> infection is not established [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6\" class=\"abstract_t\">6</a>]. Practices vary among pediatricians for the treatment of recurrent <em>C. difficile</em> infection [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/48\" class=\"abstract_t\">48</a>]. However, <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> is not recommended for the treatment of a second (or third) recurrence or for prolonged therapy due to the risk of neurotoxicity [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/6\" class=\"abstract_t\">6</a>].</p><p>Among the available options for treatment of subsequent recurrences of <em>C. difficile</em> infection in children, we suggest oral <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> given in a pulsed-tapered fashion, for example (<a href=\"image.htm?imageKey=PEDS%2F117235\" class=\"graphic graphic_table graphicRef117235 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/7,49-51\" class=\"abstract_t\">7,49-51</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>10 <span class=\"nowrap\">mg/kg</span> (maximum 125 <span class=\"nowrap\">mg/dose)</span> four times daily for 10 to 14 days, followed by</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>10 <span class=\"nowrap\">mg/kg</span> (maximum 125 <span class=\"nowrap\">mg/dose)</span> twice daily for 7 days, followed by</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>10 <span class=\"nowrap\">mg/kg</span> (maximum 125 <span class=\"nowrap\">mg/dose)</span> once daily for 7 days, followed by</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>10 <span class=\"nowrap\">mg/kg</span> (maximum 125 <span class=\"nowrap\">mg/dose)</span> every other day for 7 days, followed by</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>10 <span class=\"nowrap\">mg/kg</span> (maximum 125 <span class=\"nowrap\">mg/dose)</span> every 3 days for 2 to 8 weeks</p><p/><p>In an observational study, taper regimens that were completed with every-three-days dosing were associated with higher cure rates than regimens that ended with every-other-day dosing (81 versus 61 percent) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/51\" class=\"abstract_t\">51</a>].</p><p>Pulse-tapered <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> has been successful in clinical trials in adult patients, including a small randomized trial [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/50,52\" class=\"abstract_t\">50,52</a>], and has been used in adults and children with multiple recurrences of <em>C. difficile</em> infection [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/7,48,51\" class=\"abstract_t\">7,48,51</a>]. For patients with subsequent recurrence, previous treatment with pulse-tapered vancomycin also may be associated with a decreased risk of failure of fecal microbiota transplantation [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/53\" class=\"abstract_t\">53</a>].</p><p>Other options for the treatment of subsequent recurrences in children and adolescents may include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=fidaxomicin-drug-information\" class=\"drug drug_general\">Fidaxomicin</a> &ndash; Fidaxomicin is a macrocyclic antibiotic that is approved for the treatment of <em>C. difficile</em> infection in persons &ge;18 years of age in the United States [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/54\" class=\"abstract_t\">54</a>]. In randomized trials in adults, the efficacy of fidaxomicin was similar to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>, but the risk of recurrence was reduced [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/9,55-57\" class=\"abstract_t\">9,55-57</a>]. The use of fidaxomicin in children younger than 18 years is limited by its high cost and lack of regulatory approval. A preliminary study in children suggests that it is safe with little gastrointestinal absorption [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/58\" class=\"abstract_t\">58</a>]. A randomized trial comparing fidaxomicin and oral vancomycin in children with <em>C. difficile</em> infection is underway [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/59\" class=\"abstract_t\">59</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifaximin-pediatric-drug-information\" class=\"drug drug_pediatric\">Rifaximin</a> &ndash; Rifaximin is a nonabsorbable, broad-spectrum, rifamycin antibiotic with a good safety profile, minimal drug interactions, and high activity against most strains of <em>C. difficile</em> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/60\" class=\"abstract_t\">60</a>]. A course of rifaximin following standard treatment for <em>C. difficile</em> (&quot;rifaximin chaser&quot;) was associated with eradication of infection and decreased rates of relapse [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/61,62\" class=\"abstract_t\">61,62</a>]. Rifaximin is approved in the United States for treatment of travelers' diarrhea in individuals &ge;12 years of age; it has additional indications in other countries. Previous treatment with a rifamycin increases the risk of rifaximin resistance in the infecting strain of <em>C. difficile</em>. Rifaximin also has the potential to induce resistance to rifamycins [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/63,64\" class=\"abstract_t\">63,64</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=nitazoxanide-pediatric-drug-information\" class=\"drug drug_pediatric\">Nitazoxanide</a> &ndash; Nitazoxanide is available for the treatment of diarrhea from <em>Cryptosporidium </em>and <em>Giardia </em>in patients &ge;1 year of age. It is broadly active against most anaerobic bacteria [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/65\" class=\"abstract_t\">65</a>]. In randomized trials, nitazoxanide produced cure and relapse rates similar to <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> and <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> for initial treatment of <em>C. difficile</em> infection [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/66,67\" class=\"abstract_t\">66,67</a>]. Adult patients unresponsive to, or relapsing after, metronidazole treatment had a 66 percent response to one or more courses of nitazoxanide 500 mg twice per day [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/68\" class=\"abstract_t\">68</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Teicoplanin</strong> &ndash; Teicoplanin is a glycopeptide antibiotic (similar to <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a>) that is inexpensive and available in some countries for the treatment of gram-positive organisms. It is not available in the United States. Teicoplanin appears to be at least as efficacious as vancomycin with fewer adverse effects [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/19,21\" class=\"abstract_t\">19,21</a>].</p><p/><p class=\"bulletIndent1\">There are limited data on the use of teicoplanin in children with <em>C. difficile</em> infection.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Fecal microbiota transplantation</strong> &ndash; Fecal microbiota transplantation (FMT) is a procedure in which fecal matter obtained from a healthy donor is administered to a recipient. Several routes of administration have been described, including <span class=\"nowrap\">nasogastric/jejunal</span> tubes, enema, colonoscopy, and oral capsules. A randomized trial and several observational studies have found FMT to be effective in the treatment of recurrent <em>C. difficile</em> infection in adults [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/69-71\" class=\"abstract_t\">69-71</a>]. The use of FMT in children for recurrent <em>C. difficile</em> infection is limited to case reports and case series [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/72-75\" class=\"abstract_t\">72-75</a>]. There are few data to guide clinicians on the indications, efficacy, and safety of FMT in children, but investigation is ongoing [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/76,77\" class=\"abstract_t\">76,77</a>].</p><p/><p class=\"bulletIndent1\">FMT is discussed in detail separately. (See <a href=\"topic.htm?path=fecal-microbiota-transplantation-in-the-treatment-of-recurrent-clostridium-difficile-infection\" class=\"medical medical_review\">&quot;Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H12961978\"><span class=\"h1\">ALTERNATIVE THERAPIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several alternatives to antimicrobial therapy for <em>C. difficile</em> infection are being investigated, including toxin binding agents, passive immunotherapy (ie, monoclonal antibodies, intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a>), and probiotics. We do not suggest these therapies for children with <em>C. difficile</em> infection because their efficacy and safety have not been established.</p><p>The alternative therapies are discussed separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Toxin binding agents (see <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-treatment-and-prevention\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Treatment and prevention&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Passive immunotherapy (see <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-treatment-and-prevention\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Treatment and prevention&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Probiotics (see <a href=\"topic.htm?path=clostridium-difficile-and-probiotics#H12810765\" class=\"medical medical_review\">&quot;Clostridium difficile and probiotics&quot;, section on 'Treatment of CDAD'</a>)</p><p/><p class=\"headingAnchor\" id=\"H2258183282\"><span class=\"h1\">PREVENTION OF RECURRENCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients remain vulnerable to recurrence for many weeks following treatment of <em>C. difficile</em> infection. During this period of vulnerability, the following preventive measures may reduce the risk of recurrence:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoidance of antimicrobial treatment; if antimicrobial treatment is necessary in a high-risk patient, we suggest tailoring therapy to achieve the narrowest spectrum and shortest duration possible [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/7\" class=\"abstract_t\">7</a>] (see <a href=\"#H7\" class=\"local\">'Discontinuation of inciting antibiotics'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Following proper hand hygiene with close attention to environmental cleaning, particularly where toileting and diaper changing occur (see <a href=\"topic.htm?path=clostridium-difficile-infection-prevention-and-control#H5\" class=\"medical medical_review\">&quot;Clostridium difficile infection: Prevention and control&quot;, section on 'Hand hygiene'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoidance of gastric acid suppression (ie, proton pump inhibitors and histamine-2 receptor antagonists) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/78\" class=\"abstract_t\">78</a>] (see <a href=\"topic.htm?path=clostridium-difficile-infection-in-children-microbiology-pathogenesis-and-epidemiology#H15\" class=\"medical medical_review\">&quot;Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology&quot;, section on 'Other risk factors'</a>)</p><p/><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">OUTCOME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most children with <em>C. difficile</em> infection recover without sequelae [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/2,27,29\" class=\"abstract_t\">2,27,29</a>]. However, among hospitalized children, <em>C. difficile</em> infection is associated with increased in-hospital mortality, length of stay, and hospital cost [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/79\" class=\"abstract_t\">79</a>]. In a multicenter cohort of 7318 children hospitalized with <em>C. difficile</em> infection during 2006-2011, the 30-day all-cause mortality rate was 1.5 percent; risk factors for death included older age, gastric acid suppression, select chronic conditions (malignancy, cardiovascular disease, <span class=\"nowrap\">hematology/immunologic</span> conditions), and more severe underlying illness [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/80\" class=\"abstract_t\">80</a>].</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prevention of <em>C. difficile </em>infection is discussed separately. (See <a href=\"topic.htm?path=clostridium-difficile-infection-prevention-and-control\" class=\"medical medical_review\">&quot;Clostridium difficile infection: Prevention and control&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2826465235\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-clostridium-difficile-infection\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Clostridium difficile infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H32\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The initial step in the treatment of <em>C. difficile</em> infection is discontinuation of inciting antibiotics. If antibiotics cannot be discontinued, antimicrobial therapy should be tailored to achieve the narrowest spectrum and shortest duration as possible. (See <a href=\"#H7\" class=\"local\">'Discontinuation of inciting antibiotics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Supportive care for children with diarrhea from <em>C. difficile</em> includes correction of fluid losses and electrolyte imbalances. Hospitalization may be warranted for children with dehydration, moderate to marked toxicity, severe disease (<a href=\"image.htm?imageKey=PEDS%2F100705\" class=\"graphic graphic_table graphicRef100705 \">table 1</a>), or poor access to follow-up care. (See <a href=\"#H8\" class=\"local\">'Supportive care'</a> above and <a href=\"#H2248420511\" class=\"local\">'Indications for hospitalization'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children and adolescents with mild or moderate disease from <em>C. difficile</em> infection (<a href=\"image.htm?imageKey=PEDS%2F100705\" class=\"graphic graphic_table graphicRef100705 \">table 1</a>), we suggest oral <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> or oral <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> (<a href=\"image.htm?imageKey=PEDS%2F117235\" class=\"graphic graphic_table graphicRef117235 \">table 3</a>) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). The dose of vancomycin is 40 <span class=\"nowrap\">mg/kg</span> per day by mouth in four divided doses (maximum 125 <span class=\"nowrap\">mg/dose)</span> for 10 days. The dose of metronidazole is 30 <span class=\"nowrap\">mg/kg</span> per day by mouth in four divided doses for 10 days (maximum 500 <span class=\"nowrap\">mg/dose)</span>. (See <a href=\"#H100909150\" class=\"local\">'Mild or moderate disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children and adolescents with severe disease (<a href=\"image.htm?imageKey=PEDS%2F100705\" class=\"graphic graphic_table graphicRef100705 \">table 1</a>), we suggest oral <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> as the initial drug of choice (<a href=\"image.htm?imageKey=PEDS%2F117235\" class=\"graphic graphic_table graphicRef117235 \">table 3</a>) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). We use the standard oral dose for vancomycin: 40 <span class=\"nowrap\">mg/kg</span> per day by mouth in four divided doses (maximum 125 <span class=\"nowrap\">mg/dose)</span> for 10 days. (See <a href=\"#H100909159\" class=\"local\">'Severe disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The response to treatment of <em>C. difficile</em> infection is assessed clinically. Symptoms generally improve within 48 to 72 hours after initiation of antibiotic therapy, but diarrhea may not fully resolve for four to five days. Follow-up stool studies are not recommended. (See <a href=\"#H13\" class=\"local\">'Response to treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment failure is defined as progression of disease while on treatment or failure to improve after several days of therapy. Children with treatment failure should be evaluated (or reevaluated) for other causes of diarrhea. (See <a href=\"topic.htm?path=clostridium-difficile-infection-in-children-clinical-features-and-diagnosis#H2444666133\" class=\"medical medical_review\">&quot;Clostridium difficile infection in children: Clinical features and diagnosis&quot;, section on 'Differential diagnosis'</a> and <a href=\"#H14\" class=\"local\">'Management of treatment failure'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recurrence of <em>C. difficile</em> infection after completion of antibiotic treatment may represent a relapse of the previous infecting strain or reinfection with a new strain. For the first recurrence of <em>C. difficile</em> infection in children, we recommend a second course of treatment with the same antibiotic used for the initial episode (<a href=\"image.htm?imageKey=PEDS%2F117235\" class=\"graphic graphic_table graphicRef117235 \">table 3</a>) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Several options are available for the treatment of subsequent recurrences. We suggest oral <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> given in a pulsed-tapered manner for subsequent recurrences of <em>C. difficile </em>infection in children (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H36637750\" class=\"local\">'Management of recurrence'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients remain vulnerable to recurrent infection for many weeks following treatment for <em>C. difficile</em> infection. Antibiotics should be avoided if possible during that period of vulnerability. (See <a href=\"#H2258183282\" class=\"local\">'Prevention of recurrence'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H33\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Michael Cooperstock, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/1\" class=\"nounderline abstract_t\">Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/2\" class=\"nounderline abstract_t\">Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008; 122:1266.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/3\" class=\"nounderline abstract_t\">Nylund CM, Goudie A, Garza JM, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011; 165:451.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/4\" class=\"nounderline abstract_t\">Zilberberg MD, Tillotson GS, McDonald C. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis 2010; 16:604.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/5\" class=\"nounderline abstract_t\">Deshpande A, Pant C, Anderson MP, et al. Clostridium difficile infection in the hospitalized pediatric population: increasing trend in disease incidence. Pediatr Infect Dis J 2013; 32:1138.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Clostridium difficile. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.298.</li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/7\" class=\"nounderline abstract_t\">McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/8\" class=\"nounderline abstract_t\">Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/9\" class=\"nounderline abstract_t\">Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53:440.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/10\" class=\"nounderline abstract_t\">Tschudin-Sutter S, Tamma PD, Milstone AM, Perl TM. Predictors of first recurrence of Clostridium difficile infections in children. Pediatr Infect Dis J 2014; 33:414.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/11\" class=\"nounderline abstract_t\">Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. BMJ 2010; 340:c1296.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/12\" class=\"nounderline abstract_t\">Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009; 48:598.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/13\" class=\"nounderline abstract_t\">Vasa CV, Glatt AE. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. Am J Gastroenterol 2003; 98:354.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/14\" class=\"nounderline abstract_t\">Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117:297.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/15\" class=\"nounderline abstract_t\">Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis 2013; 56:1401.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/16\" class=\"nounderline abstract_t\">Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe clostridium difficile infection in children. Pediatr Infect Dis J 2012; 31:134.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/17\" class=\"nounderline abstract_t\">Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/18\" class=\"nounderline abstract_t\">Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59:345.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/19\" class=\"nounderline abstract_t\">Wenisch C, Parschalk B, Hasenh&uuml;ndl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/20\" class=\"nounderline abstract_t\">Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/21\" class=\"nounderline abstract_t\">Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev 2017; 3:CD004610.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/22\" class=\"nounderline abstract_t\">Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008; 52:2403.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/23\" class=\"nounderline abstract_t\">Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/24\" class=\"nounderline abstract_t\">Baines SD, O'Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62:1046.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/25\" class=\"nounderline abstract_t\">Pel&aacute;ez T, Alcal&aacute; L, Alonso R, et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46:1647.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/26\" class=\"nounderline abstract_t\">Kociolek LK, Gerding DN, Osmolski JR, et al. Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients. Antimicrob Agents Chemother 2016; 60:4896.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/27\" class=\"nounderline abstract_t\">Pai S, Aliyu SH, Enoch DA, Karas JA. Five years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management. PLoS One 2012; 7:e51728.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/28\" class=\"nounderline abstract_t\">Tschudin-Sutter S, Tamma PD, Milstone AM, Perl TM. The prediction of complicated Clostridium difficile infections in children. Infect Control Hosp Epidemiol 2014; 35:901.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/29\" class=\"nounderline abstract_t\">Schwartz KL, Darwish I, Richardson SE, et al. Severe clinical outcome is uncommon in Clostridium difficile infection in children: a retrospective cohort study. BMC Pediatr 2014; 14:28.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/30\" class=\"nounderline abstract_t\">Crews JD, Koo HL, Jiang ZD, et al. A hospital-based study of the clinical characteristics of Clostridium difficile infection in children. Pediatr Infect Dis J 2014; 33:924.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/31\" class=\"nounderline abstract_t\">Wood A, Wassil K, Edwards E. Oral Absorption of Enteral Vancomycin in a Child with Clostridium difficile Colitis and Renal Impairment. J Pediatr Pharmacol Ther 2013; 18:315.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/32\" class=\"nounderline abstract_t\">Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/33\" class=\"nounderline abstract_t\">Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/34\" class=\"nounderline abstract_t\">Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5:549.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/35\" class=\"nounderline abstract_t\">Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372:1539.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/36\" class=\"nounderline abstract_t\">Apisarnthanarak A, Khoury H, Reinus WR, et al. Severe Clostridium difficile colitis: the role of intracolonic vancomycin? Am J Med 2002; 112:328.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/37\" class=\"nounderline abstract_t\">Wenisch JM, Schmid D, Kuo HW, et al. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2012; 56:1974.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/38\" class=\"nounderline abstract_t\">Saffouri G, Khanna S, Estes L, Pardi D. Outcomes from rectal vancomycin therapy in patients with Clostridium difficile infection. Am J Gastroenterol 2014; 109:924.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/39\" class=\"nounderline abstract_t\">Lee J, Tashjian DB, Moriarty KP. Is partial colectomy the operation of choice in pediatric Clostridium difficile colitis? Pediatr Surg Int 2012; 28:603.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/40\" class=\"nounderline abstract_t\">Castillo A, L&oacute;pez J, Panadero E, et al. Conservative surgical treatment for toxic megacolon due to Clostridium difficile infection in a transplanted pediatric patient. Transpl Infect Dis 2012; 14:E34.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/41\" class=\"nounderline abstract_t\">Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984; 6 Suppl 1:S235.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/42\" class=\"nounderline abstract_t\">Al-Nassir WN, Sethi AK, Nerandzic MM, et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47:56.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/43\" class=\"nounderline abstract_t\">Kociolek LK, Patel SJ, Shulman ST, Gerding DN. Molecular epidemiology of Clostridium difficile infections in children: a retrospective cohort study. Infect Control Hosp Epidemiol 2015; 36:445.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/44\" class=\"nounderline abstract_t\">McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28:140.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/45\" class=\"nounderline abstract_t\">Kato H, Kato N, Watanabe K, et al. Relapses or reinfections: analysis of a case of Clostridium difficile-associated colitis by two typing systems. Curr Microbiol 1996; 33:220.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/46\" class=\"nounderline abstract_t\">Morinville V, McDonald J. Clostridium difficile-associated diarrhea in 200 Canadian children. Can J Gastroenterol 2005; 19:497.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/47\" class=\"nounderline abstract_t\">Nicholson MR, Thomsen IP, Slaughter JC, et al. Novel risk factors for recurrent Clostridium difficile infection in children. J Pediatr Gastroenterol Nutr 2015; 60:18.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/48\" class=\"nounderline abstract_t\">Sammons JS, Gerber JS, Tamma PD, et al. Diagnosis and management of Clostridium difficile infection by pediatric infectious diseases physicians. J Pediatric Infect Dis Soc 2013; 4:43.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/49\" class=\"nounderline abstract_t\">Tamma PD, Sandora TJ. Clostridium difficile Infection in Children: Current State and Unanswered Questions. J Pediatric Infect Dis Soc 2012; 1:230.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/50\" class=\"nounderline abstract_t\">Hota SS, Sales V, Tomlinson G, et al. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial. Clin Infect Dis 2017; 64:265.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/51\" class=\"nounderline abstract_t\">Sirbu BD, Soriano MM, Manzo C, et al. Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection. Clin Infect Dis 2017; 65:1396.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/52\" class=\"nounderline abstract_t\">McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/53\" class=\"nounderline abstract_t\">Patron RL, Hartmann CA, Allen S, et al. Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplant in Patients With Recurrent Clostridium difficile Infection. Clin Infect Dis 2017.</a></li><li class=\"breakAll\">Dificid (Fidaxomicin) prescribing information www.accessdata.fda.gov/drugsatfda_docs/label/2011/201699s000lbl.pdf (Accessed on March 26, 2015).</li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/55\" class=\"nounderline abstract_t\">Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/56\" class=\"nounderline abstract_t\">Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/57\" class=\"nounderline abstract_t\">Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55 Suppl 2:S93.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/58\" class=\"nounderline abstract_t\">O'Gorman MA, Michaels MG, Kaplan SL, et al. Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial. J Pediatric Infect Dis Soc 2017.</a></li><li class=\"breakAll\">ClinicalTrials.gov. A study to investigate the safety and efficacy of fidaxomicin (oral suspension or tablets and vancomycin (oral liquid or capsules) in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD). https://clinicaltrials.gov/ct2/show/NCT02218372 (Accessed on April 30, 2015).</li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/60\" class=\"nounderline abstract_t\">Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005; 3:201.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/61\" class=\"nounderline abstract_t\">Mattila E, Arkkila P, Mattila PS, et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2013; 37:122.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/62\" class=\"nounderline abstract_t\">Patrick Basu P, Dinani A, Rayapudi K, et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol 2010; 3:221.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/63\" class=\"nounderline abstract_t\">Curry SR, Marsh JW, Shutt KA, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009; 48:425.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/64\" class=\"nounderline abstract_t\">Miller MA, Blanchette R, Spigaglia P, et al. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol 2011; 49:4319.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/65\" class=\"nounderline abstract_t\">Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996; 40:2266.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/66\" class=\"nounderline abstract_t\">Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43:421.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/67\" class=\"nounderline abstract_t\">Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009; 48:e41.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/68\" class=\"nounderline abstract_t\">Musher DM, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007; 59:705.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/69\" class=\"nounderline abstract_t\">Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108:500.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/70\" class=\"nounderline abstract_t\">Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014; 312:1772.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/71\" class=\"nounderline abstract_t\">van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/72\" class=\"nounderline abstract_t\">Kronman MP, Nielson HJ, Adler AL, et al. Fecal microbiota transplantation via nasogastric tube for recurrent clostridium difficile infection in pediatric patients. J Pediatr Gastroenterol Nutr 2015; 60:23.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/73\" class=\"nounderline abstract_t\">Russell G, Kaplan J, Ferraro M, Michelow IC. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics 2010; 126:e239.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/74\" class=\"nounderline abstract_t\">Kahn SA, Young S, Rubin DT. Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child. Am J Gastroenterol 2012; 107:1930.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/75\" class=\"nounderline abstract_t\">Pierog A, Mencin A, Reilly NR. Fecal microbiota transplantation in children with recurrent Clostridium difficile infection. Pediatr Infect Dis J 2014; 33:1198.</a></li><li class=\"breakAll\">ClinicalTrials.gov. Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection (NCT02134392). https://clinicaltrials.gov/ct2/show/NCT02134392 (Accessed on April 07, 2015).</li><li class=\"breakAll\">ClinicalTrials.gov. Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection (NCT01972334) https://clinicaltrials.gov/ct2/show/NCT01972334 (Accessed on April 07, 2015).</li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/78\" class=\"nounderline abstract_t\">Tariq R, Singh S, Gupta A, et al. Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. JAMA Intern Med 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/79\" class=\"nounderline abstract_t\">Sammons JS, Localio R, Xiao R, et al. Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis 2013; 57:1.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcome/abstract/80\" class=\"nounderline abstract_t\">Vendetti N, Zaoutis T, Coffin SE, Sammons JS. Risk factors for in-hospital mortality among a cohort of children with Clostridium difficile infection. Infect Control Hosp Epidemiol 2015; 36:1183.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6050 Version 35.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H32\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">GENERAL MEASURES</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Discontinuation of inciting antibiotics</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Supportive care</a></li><li><a href=\"#H2248420511\" id=\"outline-link-H2248420511\">Indications for hospitalization</a></li><li><a href=\"#H3116939453\" id=\"outline-link-H3116939453\">Indications for antimicrobial therapy</a></li></ul></li><li><a href=\"#H100909150\" id=\"outline-link-H100909150\">MILD OR MODERATE DISEASE</a></li><li><a href=\"#H100909159\" id=\"outline-link-H100909159\">SEVERE DISEASE</a><ul><li><a href=\"#H2248421210\" id=\"outline-link-H2248421210\">Antimicrobial therapy</a><ul><li><a href=\"#H315875231\" id=\"outline-link-H315875231\">- Inability to tolerate oral therapy</a></li></ul></li><li><a href=\"#H2248421190\" id=\"outline-link-H2248421190\">Additional measures</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">RESPONSE TO TREATMENT</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">MANAGEMENT OF TREATMENT FAILURE</a></li><li><a href=\"#H36637750\" id=\"outline-link-H36637750\">MANAGEMENT OF RECURRENCE</a><ul><li><a href=\"#H3116940015\" id=\"outline-link-H3116940015\">First recurrence</a></li><li><a href=\"#H3116940022\" id=\"outline-link-H3116940022\">Subsequent recurrences</a></li></ul></li><li><a href=\"#H12961978\" id=\"outline-link-H12961978\">ALTERNATIVE THERAPIES</a></li><li><a href=\"#H2258183282\" id=\"outline-link-H2258183282\">PREVENTION OF RECURRENCE</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">OUTCOME</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">PREVENTION</a></li><li><a href=\"#H2826465235\" id=\"outline-link-H2826465235\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H32\" id=\"outline-link-H32\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H33\" id=\"outline-link-H33\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6050|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/100705\" class=\"graphic graphic_table\">- Severity C. difficile children</a></li><li><a href=\"image.htm?imageKey=PEDS/71790\" class=\"graphic graphic_table\">- Features of Clostridium difficile infection in children</a></li><li><a href=\"image.htm?imageKey=PEDS/117235\" class=\"graphic graphic_table\">- Treatment of Clostridium difficile infection in children</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-assessment-and-diagnosis-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">Clinical assessment and diagnosis of hypovolemia (dehydration) in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clostridium-difficile-and-probiotics\" class=\"medical medical_review\">Clostridium difficile and probiotics</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Clostridium difficile infection in adults: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-epidemiology-microbiology-and-pathophysiology\" class=\"medical medical_review\">Clostridium difficile infection in adults: Epidemiology, microbiology, and pathophysiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-treatment-and-prevention\" class=\"medical medical_review\">Clostridium difficile infection in adults: Treatment and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clostridium-difficile-infection-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">Clostridium difficile infection in children: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clostridium-difficile-infection-in-children-microbiology-pathogenesis-and-epidemiology\" class=\"medical medical_review\">Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clostridium-difficile-infection-prevention-and-control\" class=\"medical medical_review\">Clostridium difficile infection: Prevention and control</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fecal-microbiota-transplantation-in-the-treatment-of-recurrent-clostridium-difficile-infection\" class=\"medical medical_review\">Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-clostridium-difficile-infection\" class=\"medical medical_society_guidelines\">Society guideline links: Clostridium difficile infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hypovolemia-dehydration-in-children\" class=\"medical medical_review\">Treatment of hypovolemia (dehydration) in children</a></li></ul></div></div>","javascript":null}